Advancement in drug therapies may provide new treatment for Cutaneous leishmaniasis

当前使用的疗法对CL可能导致partial or complete cure. However, they associate with many limitations, including repetitive painful injections, lack of availability, expensive cost, and emergence of resistant strains. Furthermore, their efficacy remains hindered by the patient's age and immune system. Researchers investigated the pre-clinical efficacy of an immunomodulatory drug, Imiquimod and one of its analogs, EAPB0503 on two strains (Leishmania majorandLeishmania tropica) causing CL in the Middle East Area. They also tested these drugs on freshly isolated parasites from patients' biopsies and proved their leishmanicidal potency.

According to the authors, "Our findings establish Imiquimod as a strong candidate for treatingL. tropicaand show the higher potency of its analog EAPB0503 against CL." Their research is a promising advancement for the development of effective therapies for CL.